Companies: 10,795·Total market cap: $144.5T
Vanda Pharmaceuticals Inc.

Vanda Pharmaceuticals Inc.

VNDANASDAQHealthcare● Active
$5.97
$-0.07(-1.08%)
Market Cap$358708627
P/E Ratio—
52W High$9.94
52W Low$4.14
SEC Filings

Vanda Pharmaceuticals Inc. (VNDA) SEC Filings & 10-K Annual Reports

SEC EDGAR regulatory submissions (10-K, 10-Q, 8-K), latest forms, and full filing history — quick links to financials and earnings below.

SEC EDGAR · data.sec.gov · CIK 0001347178 · VNDA · NASDAQ · as of Jun 8, 2026

Filing snapshot

1,003+
Total Filings
S-8
Latest Form
2026-06-05
Most Recent
2006
Filing Since
FinancialsEarningsView All on EDGAR

Source: SEC EDGAR (data.sec.gov) · CIK 0001347178 · Updated hourly · Not investment advice

Latest Annual Report

10-K · Annual ReportFY
Filed Date
2026-02-12
Fiscal Year End
Feb 12, 2026
Accession No.
0001628280-26-007460
Primary Document
vnda-20251231.htm
View on SEC EDGARDownload PDFFiling Index
Source: data.sec.gov · CIK 0001347178 · Accession 0001628280-26-007460

Latest Key Filings

10-QQuarterly Report
10-Q
2026-05-07
View 10-Q on SEC
8-KCurrent Report
8-K
2026-06-05Material Event
View 8-K on SEC
Form 4Insider Activity
Ownership Change Disclosures

Executive & director trade disclosures. Full buy/sell sentiment analysis on the dedicated tab.

View Insider Trades Tab

SEC Filing History

Hide Form 4 / 144
S-8Employee Stock Plan Registration
S-8
2026-06-05
View
8-KCurrent Report
8-K
2026-06-05
View
SCHEDULE 13GSCHEDULE 13G
SCHEDULE 13G
2026-05-12
View
10-QQuarterly Report
10-Q
2026-05-07
View
8-KCurrent Report
8-K
2026-05-06
View
EFFECTEFFECT
EFFECT
2026-05-05
View
SCHEDULE 13G/ASCHEDULE 13G/A
SCHEDULE 13G/A
2026-04-29
View
CORRESPCORRESP
CORRESP
2026-04-24
View
3Initial Statement of Beneficial Ownership
3
2026-04-24
View
ARSARS
ARS
2026-04-23
View
DEFA14AProxy Statement (Additional)
DEFA14A
2026-04-23
View
DEF 14AProxy Statement
DEF 14A
2026-04-23
View
8-KCurrent Report
8-K
2026-04-22
View
3Initial Statement of Beneficial Ownership
3
2026-04-13
View
3Initial Statement of Beneficial Ownership
3
2026-04-13
View
Showing 1–15 of 617 filingsForm 4 / 144 hidden· 1003 total in EDGAR

About SEC Filings & 10-K Annual Reports

Data source: SEC EDGAR (data.sec.gov)  |  Updated: Hourly  |  CIK: 0001347178  |  Exchange: NASDAQ · Healthcare

Vanda Pharmaceuticals Inc. (NASDAQ: VNDA) has submitted 1,003+ documents to the U.S. Securities and Exchange Commission (SEC) since its IPO in 2006. As a Healthcare sector company with CIK 0001347178, all filings are publicly accessible via the EDGAR database at no cost.

The annual 10-K report is Vanda Pharmaceuticals Inc.'s most comprehensive regulatory disclosure. The most recent Vanda Pharmaceuticals Inc. 10-K was filed on 2026-02-12 for fiscal year ending 2026. Historical VNDA 10-K annual reports are available from 2009 through 2026.

Investors researching Vanda Pharmaceuticals Inc. SEC filings can access 10-K annual reports, quarterly 10-Q reports, material event 8-K filings, and proxy statements directly from the links above. All documents are sourced from the official SEC EDGAR system.

Source: SEC EDGAR · data.sec.gov · SEC Form 10-K · SEC Form 10-Q · SEC Form 8-K2026-06-08
Related Companies SEC Filings — Healthcare
CAPR SEC Filings →ACHV SEC Filings →ALLO SEC Filings →AVIR SEC Filings →TRDA SEC Filings →HUMA SEC Filings →SGMT SEC Filings →ARCT SEC Filings →
→ VNDA Financials→ VNDA Earnings→ VNDA Insider Trades

Frequently Asked Questions

VNDA SEC Filings · 8 questions

Vanda Pharmaceuticals Inc. (VNDA) SEC filings are publicly available on this page and on the official SEC EDGAR database at sec.gov. You can browse all 1,003+ filings and access original documents at no cost. Vanda Pharmaceuticals Inc.'s CIK is 0001347178.

VNDA SEC filingsVanda Pharmaceuticals Inc. SEC documentsfind VNDA 10-K